NCT03210935|Recruiting
French National Database of Rare Dermatological Cancers
CARADERM
Loading search results
CARADERM
Sponsor study identifier
observational
9,000
1 country
34
Study Start
November 24, 2015
Actual (reported)Primary Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 24, 2015
Actual (reported)July 4, 2017
Actual (reported)July 7, 2017
Actual (reported)December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Incidence and natural history of the 3 types of rare skin cancers
10 years
Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma
CHU Bocage
Dijon, Dijon, 21079, France
CH Le Mans
Le Mans, Le Mans, 72037, France
Laurent MORTIER, MD,PhD
University Hospital, Lille
First Submitted
July 4, 2017
First Posted
July 7, 2017
Study Start
November 24, 2015
Actual (reported)Primary Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Contact the study team to confirm eligibility.
Centre hospitalier Lyon Sud
Pierre-Bénite, Pierre-benite, 69495, France
CHU Amiens Picardie
Amiens, France
CHU Angers
Angers, France
CH Annecy Gennevois
Annecy, France
CHU Besançon
Besançon, France
CHU Avicenne
Bobigny, France
CHU Ambroise Paré
Boulogne-Billancourt, France
CHU de Brest
Brest, France
CHU de Caen
Caen, France
CHU de Clermont Ferrand
Clermont-Ferrand, France
CHU de Grenoble
Grenoble, France
CHU de Limoges
Limoges, France
Centre Léon Bérard
Lyon, France
Hôpital La Timone
Marseille, France
Hôpital St Eloi
Montpellier, France
CHU de Nancy
Nancy, France
CHU Nantes - Place Alexis Ricordeau
Nantes, France
CHU de Nice
Nice, France
CHR d'Orleans
Orléans, France
CHU Bichat
Paris, France
CHU Cochin
Paris, France
CHU St Louis
Paris, France
CHU de Bordeaux
Pessac, France
CHU de Pointe à Pitre
Pointe à Pitre, France
CHU de Poitiers
Poitiers, France
CHU de Reims
Reims, France
CHU de Rennes
Rennes, France
CHU de Rouen
Rouen, France
CHU de Strasbourg
Strasbourg, France
CHU de Toulouse - Larrey
Toulouse, France
CHU de Tours
Tours, France
Institut Gustave Roussy
Villejuif, France
Study Completion
December 31, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 22, 2026
Record last verified: 2026-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: